Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Casirivimab/imdevimab for COVID-19: real-time meta analysis of 25 studies
Covid Analysis, December 2022
https://c19early.org/rmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Regeneron (RCT) 38% 0.62 [0.29-1.33] recov. time 92 (n) 91 (n) Improvement, RR [CI] Treatment Control Regeneron (RCT) 54% 0.46 [0.19-1.13] recov. time 92 (n) 91 (n) Regeneron (RCT) 71% 0.29 [0.17-0.48] death/hosp. 18/1,355 62/1,341 Regeneron (RCT) 70% 0.30 [0.13-0.68] death/hosp. 7/736 24/748 Regeneron (RCT) 29% 0.71 [0.60-0.85] recov. time 1,355 (n) 1,341 (n) Regeneron (RCT) 29% 0.71 [0.60-0.85] recov. time 736 (n) 748 (n) Weinreich (RCT) 50% 0.50 [0.09-2.72] death 2/2,091 4/2,089 Weinreich (RCT) 67% 0.33 [0.03-3.17] death 1/1,355 3/1,341 Weinreich (RCT) -2% 1.02 [0.06-16.2] death 1/736 1/748 Weinreich (RCT) 71% 0.29 [0.17-0.48] death/hosp. 18/1,355 62/1,341 Weinreich (RCT) 70% 0.30 [0.13-0.68] death/hosp. 7/736 24/748 Weinreich (RCT) 29% 0.71 [0.58-0.87] recov. time 1,355 (n) 1,341 (n) Weinreich (RCT) 29% 0.71 [0.58-0.87] recov. time 736 (n) 748 (n) Webb 98% 0.0 [0.00-2e+05] death 0/115 57/5,536 Webb 91% 0.09 [0.01-0.63] hosp. 1/115 538/5,536 Cooper 77% 0.23 [0.03-1.65] death 1/1,148 33/8,534 Cooper 48% 0.52 [0.23-1.20] ICU 6/1,148 85/8,534 Cooper 52% 0.48 [0.35-0.64] hosp. 45/1,148 703/8,534 Kakinoki 58% 0.42 [0.17-0.92] progression 13/55 22/53 Komagamine 77% 0.23 [0.01-4.63] ventilation 0/53 2/75 Komagamine 92% 0.08 [0.00-1.32] ICU 0/53 7/75 Komagamine 68% 0.32 [0.13-0.68] progression 8/53 33/75 Komagamine 29% 0.71 [0.58-0.87] hosp. time 53 (n) 75 (n) Suzuki (PSM) -200% 3.00 [0.12-73.3] death 1/222 0/222 Suzuki 60% 0.40 [0.05-3.45] death 1/314 5/635 Suzuki (PSM) 45% 0.55 [0.31-0.96] progression 17/222 31/222 Suzuki 50% 0.50 [0.31-0.80] progression 34/314 70/365 O'Brien (DB RCT) 85% 0.15 [0.01-2.78] hosp. 0/100 3/104 O'Brien (DB RCT) 92% 0.08 [0.00-1.37] hosp./ER 0/100 6/104 O'Brien (DB RCT) 33% 0.67 [0.43-0.98] symp. case 29/100 44/104 O'Brien (DB RCT) 40% 0.60 [0.45-0.81] viral load 100 (n) 104 (n) Shopen -46% 1.46 [0.73-2.67] severe case 24/116 26/243 Osugi 24% 0.76 [0.23-2.49] hosp. 4/30 15/74 Wei 61% 0.39 [0.26-0.60] death/hosp. 23/1,116 27/5,291 Wei 61% 0.39 [0.30-0.51] hosp. 59/3,280 75/16,284 Wilden 82% 0.18 [0.05-0.50] hosp. n/a n/a Faraone 92% 0.08 [0.00-1.24] death 0/11 8/23 Faraone 94% 0.06 [0.00-0.76] oxygen 0/11 15/23 Miyashita 33% 0.67 [0.11-3.97] ventilation 2/461 3/461 Miyashita 46% 0.54 [0.35-0.82] oxygen 30/461 56/461 Levey 31% 0.69 [0.07-7.37] ICU 1/36 2/50 Levey 7% 0.93 [0.16-5.26] oxygen 2/36 3/50 Levey -108% 2.08 [0.81-5.33] hosp. 9/36 6/50 Kneidinger 97% 0.03 [0.00-264] severe case 0/3 34/215 Williams -21% 1.21 [0.14-9.86] oxygen 1/88 6/676 Williams -1% 1.01 [0.12-8.01] severe case 1/88 7/676 Williams 14% 0.86 [0.10-6.63] hosp. 1/88 8/676 Gershengorn -95% 1.95 [0.86-4.18] hosp. 369 (n) 5,915 (n) Gershengorn (PSM) -105% 2.05 [1.23-3.42] hosp. 21/369 41/1,476 Gershengorn (PSM) -100% 2.00 [0.99-4.06] hosp. 11/213 22/852 Gershengorn (PSM) -111% 2.11 [1.00-4.44] hosp. 10/156 19/624 Horby (RCT) 6% 0.94 [0.86-1.02] death 943/4,839 1,029/4,946 Horby (RCT) -1% 1.01 [0.90-1.14] ventilation 484/4,556 488/4,642 Horby (RCT) 21% 0.79 [0.69-0.91] death 396/1,633 452/1,520 Horby (RCT) 13% 0.87 [0.73-1.05] ventilation 190/1,599 202/1,484 Somersa.. (DB RCT) 36% 0.64 [0.44-0.93] death 59/804 45/393 Somersa.. (DB RCT) 56% 0.44 [0.26-0.76] death 24/360 24/160 Somersa.. (DB RCT) 21% 0.79 [0.44-1.40] death 26/369 18/201 Somersa.. (DB RCT) 31% 0.69 [0.50-0.95] death/int. 82/804 58/393 Somersa.. (DB RCT) 30% 0.70 [0.52-0.94] no disch. 90/804 63/393 McCreary (PSM) 93% 0.07 [0.01-0.51] death 1/652 29/1,304 McCreary (PSM) 56% 0.44 [0.28-0.68] death/hosp. 22/652 101/1,304 McCreary (PSM) 48% 0.52 [0.33-0.82] hosp. 22/652 85/1,304 McCreary (PSM) 40% 0.60 [0.43-0.85] hosp./ER 40/652 133/1,304 Regeneron (RCT) 94% 0.06 [0.00-1.10] symp. case 0/186 8/223 Regeneron (RCT) 48% 0.52 [0.25-1.07] cases 10/186 23/223 Regeneron (DB RCT) 92% 0.08 [0.00-1.36] hosp. 0/841 6/842 Regeneron (DB RCT) 81% 0.19 [0.12-0.30] cases 20/841 108/842 Regeneron (DB RCT) 82% 0.18 [0.08-0.41] cases 7/841 38/842 Regeneron (DB RCT) 89% 0.11 [0.01-2.06] hosp./ER 0/753 4/752 Regeneron (DB RCT) 81% 0.19 [0.10-0.35] symp. case 11/753 59/752 Regeneron (DB RCT) 62% 0.38 [0.23-0.61] recov. time 753 (n) 752 (n) Regeneron (DB RCT) 69% 0.31 [0.17-0.55] viral time 753 (n) 752 (n) Isa (DB RCT) 93% 0.07 [0.01-0.28] symp. case 3/729 13/240 Isa (DB RCT) 93% 0.07 [0.01-0.28] cases 0/729 10/240 Casirivimab/imdevimab COVID-19 outcomes c19early.org/r Dec 2022 Favors casirivimab/im.. Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit